Glaukos Co. (NYSE:GKOS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Glaukos Co. (NYSE:GKOS - Get Free Report) has been given an average rating of "Moderate Buy" by the thirteen research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $147.75.

A number of analysts have recently issued reports on the stock. Stephens raised shares of Glaukos to a "strong-buy" rating in a research report on Monday, December 2nd. UBS Group began coverage on shares of Glaukos in a research note on Friday, December 6th. They set a "buy" rating and a $182.00 target price for the company. JPMorgan Chase & Co. upped their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Truist Financial boosted their target price on Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. Finally, Wells Fargo & Company increased their price target on shares of Glaukos from $145.00 to $153.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. The trade was a 2.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gilbert H. Kliman sold 10,000 shares of the business's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the transaction, the director now owns 32,336 shares of the company's stock, valued at $4,859,454.08. This trade represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,603 shares of company stock worth $2,605,678 in the last ninety days. 6.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. bought a new stake in Glaukos during the third quarter worth $25,000. Harvest Fund Management Co. Ltd grew its holdings in Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock worth $117,000 after purchasing an additional 860 shares during the period. KBC Group NV increased its position in Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock worth $188,000 after buying an additional 201 shares during the last quarter. Brighton Jones LLC bought a new stake in Glaukos in the second quarter valued at approximately $208,000. Finally, EWA LLC bought a new position in shares of Glaukos during the 3rd quarter worth approximately $209,000. 99.04% of the stock is currently owned by institutional investors.

Glaukos Trading Up 0.1 %

Shares of GKOS traded up $0.09 during trading hours on Friday, hitting $156.60. 529,055 shares of the company were exchanged, compared to its average volume of 558,098. Glaukos has a one year low of $83.90 and a one year high of $161.13. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm has a fifty day simple moving average of $145.94 and a 200-day simple moving average of $133.49.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. During the same quarter in the previous year, the company earned ($0.50) EPS. The business's revenue for the quarter was up 23.9% compared to the same quarter last year. As a group, analysts anticipate that Glaukos will post -1.89 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.